基因组检测在不同人群中乳腺癌预后与预测价值:综述
本综述评估多基因检测(主要聚焦21基因、70基因和50基因特征检测)在不同种族和民族人群中乳腺癌复发与生存结局的风险估计分布、预测能力及影响。结果显示,黑人女性更常见侵袭性肿瘤表型(如luminal B型和基底样亚型),且校正基因组检测结果和分子亚型后差异仍持续存在,提示基因组因素无法完全解释临床结局差异。综述支持基因组检测作为预后和治疗决策的有价值工具,但不能完全反映与种族和民族结局差异相关的因素。
要点
- 多基因检测(21、70、50基因特征)用于乳腺癌预后与治疗决策有价值。
- 黑人女性更常见luminal B型和基底样亚型等侵袭性肿瘤表型,与更差结局相关。
- 校正基因组检测结果和分子亚型后差异仍持续,基因组因素无法完全解释结局差异。
核心结论
- 本综述支持基因组检测作为乳腺癌预后和治疗决策的有价值工具,但不能完全反映与种族和民族结局差异相关的因素。
- 需要将基因组数据与对社会决定因素和系统性不平等的更深理解相结合的综合方法,以确保所有患者公平受益于个体化医学进展。
研究设计与样本
- 本综述评估多基因检测的风险估计分布,主要聚焦21基因、70基因和50基因特征检测。
- 综述评估这些检测在不同种族和民族人群中对乳腺癌复发和生存结局的预测能力及影响。
主要发现
- 黑人女性更可能具有侵袭性肿瘤表型,如luminal B型和基底样亚型,导致更差结局。
- 校正基因组检测结果和分子亚型后这些差异仍持续存在,提示基因组因素无法完全解释临床结局差异。
- 来自2项随机临床试验的亚组分析显示,21基因特征检测的预测价值在不同种族组间未见明显差异。
关键数值与推荐
- 主要评估的基因组检测为21基因、70基因和50基因特征检测。
- 2项随机临床试验的亚组分析显示21基因特征检测预测价值在不同种族组间未见明显差异。
临床怎么用
- 综述指出基因组检测可用于提供预后信息和治疗决策参考。
- 综述强调需要综合方法整合基因组数据与社会决定因素和系统性不平等,以确保公平受益。
局限性
- 需要进一步研究以确保基因组检测在不同人群中得到公平校准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Despite recent declines in breast cancer mortality rates, substantial disparities persist among race and ethnicity groups. Genomic assays are crucial for understanding the biological characteristics of tumors, providing valuable insights into prognosis and treatment response. Their integration into personalized clinical decision-making has notably enhanced outcomes, making these assays particularly valuable for underrepresented populations, which often face disproportionately poorer prognoses. Expanding research to evaluate the performance and predictive value of these assays across diverse groups is essential to ensure equitable benefits for all patients. OBSERVATIONS: This review evaluated the distribution of risk estimates from multigene assays, primarily focusing on 21-, 70-, and 50-gene signature assays, their predictive capabilities and impact on breast cancer recurrence and survival outcomes across race and ethnicity groups. Findings indicate that racial and ethnic disparities in breast cancer outcomes were influenced by a complex interplay of biological, social, and systemic factors. Black women were more likely to have aggressive tumor phenotypes, such as luminal B and basal-like subtypes, which contributed to poorer outcomes. These disparities persist even after adjusting for genomic assay results and molecular subtypes, suggesting that genomic factors alone cannot fully explain differences in clinical outcomes. Although subgroup analyses from 2 randomized clinical trials showed no apparent differences in the 21-gene signature's predictive value across racial groups, further research is needed to ensure that genomic assays are equitably calibrated for diverse populations. CONCLUSIONS AND RELEVANCE: This review supports genomic assays as valuable tools for informing prognosis and treatment decisions in breast cancer; however, they do not fully capture factors associated with racial and ethnic disparities in outcomes. A comprehensive approach that integrates genomic data with a deeper understanding of social determinants and systemic inequities is essential to ensure all patients benefit equitably from advancements in personalized medicine.
引用
- Abdou Y, Kantor O, Racz J, et al. Prognostic and Predictive Insights From Genomic Assays for Breast Cancer in Diverse Populations: A Review. JAMA Oncol. 2025. PMID: 40178824. doi:10.1001/jamaoncol.2025.0178
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。